HEALTH STATE UTILITIES IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TREATED WITH CLADRIBINE TABLETS
Author(s)
Wong SL1, Hohnhorst Pv1, Hettle R2, Konings P3
1EMD Serono, Inc., Billerica, MA, USA, 2PAREXEL International, London, UK, 3PAREXEL International, Stockholm, Sweden
OBJECTIVES: To estimate the health state utility (HSU) of patients with relapsing remitting multiple sclerosis treated with oral cladribine 3.5mg/kg or placebo using EuroQoL 5-dimension (EQ-5D-3L) data collected in the CLARITY (NCT00213135) and CLARITY Extension studies (NCT00641537). METHODS: HSU were derived from the EQ-5D-3L questionnaires administered at baseline, during scheduled visits (24-week intervals), and at unscheduled visits coinciding with relapses in CLARITY and CLARITY Extension using the UK tariff. Mean and standard deviations (SD) for HSU and Visual Analogue Scale (VAS) were generated for scheduled and unscheduled assessments. Multivariate linear mixed modelling was used to identify factors associated with HSU, and included Expanded Disability Status Scale (EDSS), treatment, and baseline demographics RESULTS: CONCLUSIONS: Consistent HSU values were observed across CLARITY and CLARITY Extension. Key predictors of HSU were EDSS, baseline HSU, and sex. Overall, findings indicate EDSS is a determinant of HSU, with no additional independent treatment effect on HSU after adjusting for EDSS.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PND47
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Neurological Disorders